

UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY

<b>IN RE: VALSARTAN, LOSARTAN, AND IRBESARTAN PRODUCTS LIABILITY LITIGATION</b>	<b>MDL No. 2875</b>  <b>HON. ROBERT B. KUGLER</b>
<b>THIS DOCUMENT RELATES TO ALL CASES</b>	

**NOTICE TO TAKE VIDEOTAPED ORAL DEPOSITION**

TO: **Lori G. Cohen, Esq.,  
GREENBERG TRAURIG, LLP  
Terminus 200, 3333 Piedmont Road NE, Suite 2500  
Atlanta, GA 30305**  
*Attorneys for Defendants Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical  
Industries, Ltd., Actavis, LLC, Arrow Pharm Malta Ltd., and Actavis Pharma (hereinafter  
“Defendants”).*

Please take notice that pursuant to Federal Rule of Civil Procedure 30, and other applicable Rules, including the Local Civil Rules, and the applicable Orders of the Court, Plaintiffs, by and through their counsel, will take the videotaped deposition of **Kevin Galownia**, on February 18, 2021, at 9:00 a.m. eastern time, and continuing until completion, via remote deposition while the witness is at her home or office or other location agreed to by the parties, in accordance with the Fact Witness Deposition Protocol, Case Management Order #20, filed November 17, 2020 (Document 632). The deposition shall first address the Federal Rule of Civil Procedure 30(b)(6) topics listed on Exhibit A attached, followed by deposition of the witness in his individual capacity. The witness shall produce the documents requested at Exhibit B, attached hereto, at least 5 days in advance of the deposition.

Pursuant to the meet and confer between the parties, a translator will not be provided.

**TAKING ATTORNEYS FOR PLAINTIFFS:**

David J. Stanoch, Esq.  
Kanner & Whiteley, L.L.C.  
701 Camp St.  
New Orleans, LA 70130  
Telephone: 504-524-5777  
[d.stanoch@kanner-law.com](mailto:d.stanoch@kanner-law.com)

The videotaped deposition will be taken before a person authorized by law to administer oaths, pursuant to Rule 28 of the Federal Rules of Civil Procedure.

January 28, 2021

**PLAINTIFFS' CO-LEAD COUNSEL**

By:     /s/ David J. Stanoch      
DAVID J. STANOCH  
Kanner & Whiteley, L.L.C.  
701 Camp St.  
New Orleans, LA 70130  
Telephone: 504-524-5777

**EXHIBIT A**

**RULE 30(B)(6) TOPICS (*see* ECF 651-1 for full list of Topics to Teva)**

52. The pricing of Teva's valsartan finished dose that was ultimately sold in the United States.

53. The gross and net profits to Teva from the sale of Teva's valsartan finished dose in the United States.

55. The Teva valsartan finished dose sales and pricing data produced by you in this litigation (sample documents to be provided at least 30 days ahead of deposition during meet and confer process).

56. Teva's acquisition and ownership of entities that purchased valsartan API and sold valsartan finished dose intended for use in the United States.

**EXHIBIT B**

**DOCUMENT REQUESTS**

1. The most recent resume/Curriculum Vitae and LinkedIn profile for Kevin Galownia.
2. The complete production of Kevin Galownia's relevant custodial documents, including those maintained on personal computers or electronic devices, to the extent not produced prior.

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

<b>IN RE: VALSARTAN, LOSARTAN, AND IRBESARTAN PRODUCTS LIABILITY LITIGATION</b>	<b>MDL No. 2875</b>  <b>HON. ROBERT B. KUGLER</b>
<b>THIS DOCUMENT RELATES TO ALL CASES</b>	

**CERTIFICATE OF SERVICE**

I hereby certify that on January 28, 2021, I caused the foregoing document to be electronically filed with the Clerk of the court using CM/ECF system which will send notification of such filing to the CM/ECF participants registered to receive service in this MDL.

PLAINTIFFS' CO-LEAD COUNSEL

By: /s/ David J. Stanoch  
DAVID J. STANOCH  
Kanner & Whiteley, L.L.C.  
701 Camp St.  
New Orleans, LA 70130  
Telephone: 504-524-5777